Centaurus Financial Inc. Makes New Investment in Aurinia Pharmaceuticals Inc $AUPH

Centaurus Financial Inc. purchased a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) during the 2nd quarter, HoldingsChannel reports. The fund purchased 65,576 shares of the biotechnology company’s stock, valued at approximately $1,113,000.

Other large investors have also recently modified their holdings of the company. Corient Private Wealth LP purchased a new position in shares of Aurinia Pharmaceuticals during the second quarter worth about $355,000. Bank of America Corp DE purchased a new stake in Aurinia Pharmaceuticals in the second quarter valued at approximately $3,820,000. Freestone Grove Partners LP bought a new stake in Aurinia Pharmaceuticals during the second quarter valued at approximately $979,000. Man Group plc bought a new stake in Aurinia Pharmaceuticals during the second quarter valued at approximately $1,424,000. Finally, Jupiter Topco LLC purchased a new position in Aurinia Pharmaceuticals in the 2nd quarter worth approximately $10,219,000. Institutional investors own 36.83% of the company’s stock.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CEO Kevin Tang purchased 206,005 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was acquired at an average cost of $15.28 per share, for a total transaction of $3,147,756.40. Following the completion of the transaction, the chief executive officer directly owned 13,044,106 shares in the company, valued at approximately $199,313,939.68. This represents a 1.60% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 10.40% of the stock is currently owned by insiders.

Aurinia Pharmaceuticals Trading Down 0.4%

AUPH stock opened at $16.48 on Friday. The company has a market capitalization of $2.19 billion, a PE ratio of 7.20 and a beta of 1.42. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.97 and a current ratio of 5.42. Aurinia Pharmaceuticals Inc has a one year low of $10.34 and a one year high of $19.25. The company’s 50 day moving average price is $15.98 and its two-hundred day moving average price is $15.49.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. The company had revenue of $58.57 million during the quarter, compared to analysts’ expectations of $80.45 million. As a group, analysts predict that Aurinia Pharmaceuticals Inc will post 0.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AUPH. Weiss Ratings reissued a “hold (c+)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, August 12th. Bloom Burton upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Wall Street Zen cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Royal Bank Of Canada raised their price target on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Friday, August 7th. Finally, Zacks Research lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $17.67.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.